Which has stronger valuation and earnings, SRRK or KARD?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A Kardigan N/A N/A N/A N/A N/A

Is SRRK or KARD more profitable?

Kardigan's return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Kardigan N/A N/A N/A

Does the media prefer SRRK or KARD?

In the previous week, Scholar Rock had 28 more articles in the media than Kardigan. MarketBeat recorded 31 mentions for Scholar Rock and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat Scholar Rock's score of 0.76 indicating that Kardigan is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 15 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, KARD or MIRM?

Kardigan has higher earnings, but lower revenue than Mirum Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A N/A N/A N/A Mirum Pharmaceuticals $521.31M 12.13 -$23.36M -$14.55 N/A

Does the media prefer KARD or MIRM?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Kardigan. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat Mirum Pharmaceuticals' score of 0.64 indicating that Kardigan is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CGON or KARD?

Kardigan has lower revenue, but higher earnings than CG Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,626.24 -$160.99M -$2.69 N/A Kardigan N/A N/A N/A N/A N/A

Is CGON or KARD more profitable?

Kardigan has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Kardigan's return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -25.20% -23.98% Kardigan N/A N/A N/A

Does the media prefer CGON or KARD?

In the previous week, CG Oncology had 4 more articles in the media than Kardigan. MarketBeat recorded 7 mentions for CG Oncology and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat CG Oncology's score of 0.94 indicating that Kardigan is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, TVTX or KARD?

Kardigan has lower revenue, but higher earnings than Travere Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Travere Therapeutics $490.73M 12.19 -$25.55M -$0.46 N/A Kardigan N/A N/A N/A N/A N/A

Does the media favor TVTX or KARD?

In the previous week, Travere Therapeutics had 5 more articles in the media than Kardigan. MarketBeat recorded 8 mentions for Travere Therapeutics and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat Travere Therapeutics' score of 1.03 indicating that Kardigan is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ORKA or KARD?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A Kardigan N/A N/A N/A N/A N/A

Is ORKA or KARD more profitable?

Kardigan's return on equity of 0.00% beat Oruka Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -21.65% -20.88% Kardigan N/A N/A N/A

Does the media refer more to ORKA or KARD?

In the previous week, Oruka Therapeutics had 11 more articles in the media than Kardigan. MarketBeat recorded 14 mentions for Oruka Therapeutics and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat Oruka Therapeutics' score of 0.21 indicating that Kardigan is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kardigan (KARD) Competitors

$17.31 -1.25 (-6.73%)

As of 04:00 PM Eastern

Compare

KARD vs. SRRK, MIRM, CGON, TVTX, and ORKA

Should you buy Kardigan stock or one of its competitors? Kardigan's main competitors and comparable companies include Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), Travere Therapeutics (TVTX), and Oruka Therapeutics (ORKA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kardigan compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Scholar Rock presently has a consensus price target of $66.00, indicating a potential upside of 33.68%. Kardigan has a consensus price target of $42.25, indicating a potential upside of 144.08%. Given Kardigan's higher possible upside, analysts plainly believe Kardigan is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.94
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Scholar Rock had 28 more articles in the media than Kardigan. MarketBeat recorded 31 mentions for Scholar Rock and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat Scholar Rock's score of 0.76 indicating that Kardigan is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	15 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Kardigan	N/A	N/A	N/A	N/A	N/A

Kardigan's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Kardigan	N/A	N/A	N/A

Summary

Scholar Rock beats Kardigan on 6 of the 10 factors compared between the two stocks.

How does Kardigan compare to Mirum Pharmaceuticals?

Kardigan (NASDAQ:KARD) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Kardigan. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat Mirum Pharmaceuticals' score of 0.64 indicating that Kardigan is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kardigan has higher earnings, but lower revenue than Mirum Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	N/A	N/A	N/A
Mirum Pharmaceuticals	$521.31M	12.13	-$23.36M	-$14.55	N/A

Kardigan has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Kardigan's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Kardigan presently has a consensus price target of $42.25, suggesting a potential upside of 144.08%. Mirum Pharmaceuticals has a consensus price target of $137.31, suggesting a potential upside of 41.02%. Given Kardigan's higher probable upside, equities analysts plainly believe Kardigan is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Summary

Kardigan and Mirum Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Kardigan compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kardigan has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. Kardigan's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Kardigan	N/A	N/A	N/A

In the previous week, CG Oncology had 4 more articles in the media than Kardigan. MarketBeat recorded 7 mentions for CG Oncology and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat CG Oncology's score of 0.94 indicating that Kardigan is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology currently has a consensus price target of $87.78, indicating a potential upside of 18.43%. Kardigan has a consensus price target of $42.25, indicating a potential upside of 144.08%. Given Kardigan's higher probable upside, analysts plainly believe Kardigan is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kardigan has lower revenue, but higher earnings than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,626.24	-$160.99M	-$2.69	N/A
Kardigan	N/A	N/A	N/A	N/A	N/A

Summary

CG Oncology beats Kardigan on 6 of the 11 factors compared between the two stocks.

How does Kardigan compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

In the previous week, Travere Therapeutics had 5 more articles in the media than Kardigan. MarketBeat recorded 8 mentions for Travere Therapeutics and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat Travere Therapeutics' score of 1.03 indicating that Kardigan is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kardigan has lower revenue, but higher earnings than Travere Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	12.19	-$25.55M	-$0.46	N/A
Kardigan	N/A	N/A	N/A	N/A	N/A

Travere Therapeutics currently has a consensus target price of $68.00, indicating a potential upside of 7.12%. Kardigan has a consensus target price of $42.25, indicating a potential upside of 144.08%. Given Kardigan's higher probable upside, analysts clearly believe Kardigan is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kardigan has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Kardigan's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Kardigan	N/A	N/A	N/A

Summary

Kardigan beats Travere Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Kardigan compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Kardigan	N/A	N/A	N/A	N/A	N/A

Kardigan's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Kardigan	N/A	N/A	N/A

Oruka Therapeutics currently has a consensus target price of $133.00, suggesting a potential upside of 42.17%. Kardigan has a consensus target price of $42.25, suggesting a potential upside of 144.08%. Given Kardigan's higher probable upside, analysts clearly believe Kardigan is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 11 more articles in the media than Kardigan. MarketBeat recorded 14 mentions for Oruka Therapeutics and 3 mentions for Kardigan. Kardigan's average media sentiment score of 1.17 beat Oruka Therapeutics' score of 0.21 indicating that Kardigan is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Oruka Therapeutics beats Kardigan on 5 of the 9 factors compared between the two stocks.

Get Kardigan News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KARD vs. The Competition

Export

Metric	Kardigan	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.74B	$3.85B	$7.22B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	N/A	14.33	273.52	25.33
Price / Sales	N/A	1,419.91	647.05	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	N/A	15.15	10.35	6.24
Net Income	N/A	-$22.78M	$3.49B	$358.55M
7 Day Performance	-12.04%	-3.96%	-1.78%	-2.07%
1 Month Performance	-14.31%	-2.59%	-1.48%	-4.80%
1 Year Performance	N/A	37.19%	18.20%	5.44%

Kardigan Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KARD Kardigan	3.9069 of 5 stars	$17.31 -6.7%	$42.25 +144.1%	N/A	$1.74B	N/A	N/A	241	Positive News Analyst Forecast High Trading Volume
SRRK Scholar Rock	3.2521 of 5 stars	$55.41 -0.5%	$58.77 +6.1%	+48.5%	$6.78B	N/A	N/A	289	News Coverage Positive News Analyst Forecast Gap Down
MIRM Mirum Pharmaceuticals	2.798 of 5 stars	$98.22 -2.4%	$137.31 +39.8%	+26.6%	$6.53B	$618.07M	N/A	433
CGON CG Oncology	2.8842 of 5 stars	$72.35 +0.5%	$87.78 +21.3%	+109.7%	$6.38B	$4.04M	N/A	142	Positive News
TVTX Travere Therapeutics	1.7341 of 5 stars	$66.17 -2.0%	$64.09 -3.1%	+171.7%	$6.36B	$591.33M	N/A	497	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KARD) was last updated on 9/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kardigan (KARD) Competitors

KARD vs. SRRK, MIRM, CGON, TVTX, and ORKA

How does Kardigan compare to Scholar Rock?

Summary

How does Kardigan compare to Mirum Pharmaceuticals?

Summary

How does Kardigan compare to CG Oncology?

Summary

How does Kardigan compare to Travere Therapeutics?

Summary

How does Kardigan compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KARD vs. The Competition

Kardigan Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kardigan (KARD) Competitors

KARD vs. SRRK, MIRM, CGON, TVTX, and ORKA

How does Kardigan compare to Scholar Rock?

Do analysts prefer SRRK or KARD?

Do insiders and institutionals have more ownership in SRRK or KARD?

Does the media prefer SRRK or KARD?

Which has stronger valuation and earnings, SRRK or KARD?

Is SRRK or KARD more profitable?

Summary

How does Kardigan compare to Mirum Pharmaceuticals?

Does the media prefer KARD or MIRM?

Which has stronger valuation and earnings, KARD or MIRM?

Is KARD or MIRM more profitable?

Do analysts rate KARD or MIRM?

Summary

How does Kardigan compare to CG Oncology?

Do insiders and institutionals have more ownership in CGON or KARD?

Is CGON or KARD more profitable?

Does the media prefer CGON or KARD?

Do analysts recommend CGON or KARD?

Which has better earnings and valuation, CGON or KARD?

Summary

How does Kardigan compare to Travere Therapeutics?

Does the media favor TVTX or KARD?

Which has higher valuation & earnings, TVTX or KARD?

Do analysts prefer TVTX or KARD?

Is TVTX or KARD more profitable?

Summary

How does Kardigan compare to Oruka Therapeutics?

Which has stronger valuation & earnings, ORKA or KARD?

Is ORKA or KARD more profitable?

Do analysts prefer ORKA or KARD?

Do insiders and institutionals hold more shares of ORKA or KARD?

Does the media refer more to ORKA or KARD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KARD vs. The Competition

Kardigan Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools